The FDA approves an Eli Lilly (LLY) cancer drug, Retevmo, for new uses. George Tsilis discusses LLY as UBS upgraded LLY to buy from neutral and raised its price target to $363. He talks about how LLY hit 52-week high on July 15th and is up over 10% YTD. He then goes over how LLY, as well as other Pharma stocks have been and continue to be recession resistant. He then demonstrates an example trade using LLY. Tune in to find out more about the stock market today.
22 Sep 2022
Trading 360
29 Jun 2023
Morning Trade Live
08 Aug 2023
The Watch List
26 Jun 2023
Market On Close
09 Aug 2023
Market On Close
27 Jun 2023
Trading 360
10 Jul 2023